PharmaShots | Incisive News in 3 Shots

Subscribe Now

nonalcoholic steatohepatitis

Arrowhead Entered into an Exclusive License Agreement with GSK to Develop and Commercialize ARO-HSD for Nonalcoholic Steatohepatitis

Arrowhead Entered into an Exclusive License Agreement with GSK to Develop and Commercialize ARO-HSD for Nonalcoholic Steatohepatit...

November 23, 2021

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

August 4, 2020

Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis

Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis

July 2, 2019

Gilead Collaborates with Insitro to Discover and Develop Novel Therapies in Nonalcoholic Steatohepatitis (NASH) for 3yrs.

Gilead Collaborates with Insitro to Discover and Develop Novel Therapies in Nonalcoholic Steatohepatitis (NASH) for 3yrs.

April 17, 2019

Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis...

February 13, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us